3rd Annual

Ophthalmology Times

Research Scholar Honoree Program

October 10, 2019 — San Francisco Marriott Marquis, San Francisco, CA

This medical education program is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Learning Method and Medium

This educational activity consists of research, abstract submissions, live presentations, and enduring article distribution.

This is a non-accredited educational activity.

Activity Description

This activity uses an expert panel of judges to provide insight and feedback to fellows and residents on research abstracts, live presentations, and what the research contributes to the retinal community.

Target Audience

This educational activity is intended for retina fellows and residents.

Learning Objectives

Upon completion of this program, participants will be better able to:

- Recognize unique and notable research in the area of retinal disease;
- Identify areas of emerging treatment options;
- Apply new information acquired to improve patient outcomes.

Grantor Statement

This educational activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosures

Thomas A. Albini, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Abbvie, Alcon Pharmaceuticals, Allergan, Clearside, Genentech, Mallinckrodt, Novartis, pSividia, and Santen, Inc.

Sophie J. Bakri, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Alimera, Allegro Ophthalmics, Allergan, Eyepoint, Kala Pharmaceuticals, Genentech, Novartis, and Roche

Andrew A. Moshfeghi, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Alimera, Allegro, Allergan, Clearside, EyePoint, Genentech, Novartis, and Regeneron

Equity: Pr3vent and OptiSTENT, Inc.

Research Support: Regeneron, Novartis, and Genentech

Rishi P. Singh, MD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Alcon, Bausch and Lomb, Genentech, Novartis, Optos, Regeneron, and Zeiss

Research Support: Apellis

Philip J. Rosenfeld, MD, PhD has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Consultant: Apellis, Astellas Institute for Regenerative Medicine, Boehringer-Ingelheim, Carl Zeiss Meditec, Chengdu Kanghong Biotech, Hemera Biosciences, Isarna Therapeutics, Lin Bioscience, Ocudyne, Ocunexus, Unity Biotechnology, and Valitor

Research Support: Boehringer Ingelheim, Carl Zeiss Meditec, and Stealth Biotherapeutics,

Equity: Apellis, Ocudyne, and Verana Health

Ophthalmology Times Editorial Support Disclosures

Peter J. McDonnell, MD, has a financial agreement or affiliation during the past year with the following commercial interests in the form of:

Board of Directors: Allergan, Plc.

Sheryl Stevenson has no relevant commercial relationships

Michelle Dalton, ELS, has no relevant commercial relationships.

About the Program

This program is dedicated to the education of fellows and residents and offers a unique opportunity to share notable retina research with peers and mentors. This program is supported by an unrestricted grant from Regeneron Pharmaceuticals.

Program Description

Ophthalmology Times requested ophthalmic institutions to nominate fellows and residents involved in unique/notable research in retinal disease. Qualifying fellows and residents have been asked to submit an abstract, a short summary, and a presentation to include what the research contributes to the retinal community. All submissions have been reviewed by a panel of expert judges, and the top research submissions have been invited to present here today in San Francisco. Today's presentations and feedback provided by our expert panel of judges, promises to provide all attendees with a rich educational experience.

Opening up the awards portion of the day will be a keynote address given by Philip J. Rosenfeld, MD, PhD. At the conclusion of today, the Top 5 Finalists will be selected and will be featured in a peer-reviewed supplement in 2020. To make this valuable education available to a broader audience, all of those selected to present here today will be published online within ophthalmologytimes.com and the top 5 summaries will be featured in an edition of *Ophthalmology Times*.

Peter J. McDonnell, MD

Director of The Wilmer Eye Institute; William Holland Wilmer Professor of Ophthalmology; Chief Medical Editor, *Ophthalmology Times*

Sheryl Stevenson

Group Editorial Director, MJH Life Sciences, *Ophthalmology Times*

Rishi P. Singh, MD (Program Chair) is a staff surgeon at the Cole Eye Institute, Cleveland Clinic and Associate Professor of Ophthalmology at the Lerner College of Medicine in Cleveland, OH. He also currently serves as the medical director of informatics at the Cleveland Clinic. He received his bachelors and medical degrees from Boston University and completed his residency at the Massachusetts Eye and Ear Infirmary Harvard Combined Program in Boston, Massachusetts. Dr. Singh then completed a medical and surgical fellowship at the Cole Eye Institute in Cleveland, OH.

He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy, retinal detachment, and age-related macular degeneration. Dr. Singh has authored greater than 140 peer reviewed publications, books, and book chapters and serves as the principal investigator of numerous national clinical trials advancing the treatment of retinal disease. He is frequently invited to speak at national and international meetings, as well as continuing medical education seminars.

Dr. Singh is the current president on the Retina World Congress and is on the board of the American Society of Retina Specialists. Dr. Singh is the associate editor of Ophthalmic Surgery, Lasers and Imaging Retina Journal (OSLI-Retina) and is the editor of the American Journal of Ophthalmic Clinical Trials. He maintains a strong relationship with drug development and commercial entities by serving on scientific advisory boards.

Dr. Singh's current work focuses on electronic medical records implementation, big data analyses, machine learning, lean process improvement, and decision support modules for clinical practice. Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award, American Society of Retina Specialists Senior Honor Award, and the American Society of Retina Specialists Young Investigator Award.

Thomas A. Albini, MD received a Bachelor of Arts degree, Magna Cum Laude, from Princeton University and a Doctor of Medicine degree from Johns Hopkins University School of Medicine. He completed an ophthalmology residency at Doheny Eye Institute of the University of Southern California. He then completed a uveitis clinical and research fellowship at Doheny Eye Institute and a vitreoretinal surgery fellowship at Cullen Eye Institute of the Baylor College of Medicine. Dr. Albini currently is Professor of Clinical Ophthalmology at the Bascom Palmer Eye Institute in Miami, FL and serves as director of the vitreoretinal surgery fellowship. His research interests include treatment and diagnosis of uveitis and macular disorders. He has recently published multiple papers on the risks of alternative, unproven "stem cell" therapies for eye disorders, leading to significant changes in US federal policy. He is a member of numerous professional and honorary societies, including the American Academy of Ophthalmology, the American Society of Retina Specialists, The Retina Society, the Macula Society, the Club Jules Gonin, the American Uveitis Society and the International Uveitis Study Group. He served as president of the Vit-Buckle Society. He also served as Editor-in-Chief of the American Society of Retina Specialists' web site for 4 years. Dr. Albini has received numerous awards including an Achievement Award from the American Academy of Ophthalmology and a Senior Achievement Award from the American Society of Retina Specialists. He has authored over 130 peer-reviewed articles on clinical and experimental topics in vitreoretinal disease and uveitis.

Sophie J. Bakri, MD is Professor of Ophthalmology at Mayo Clinic, Rochester, MN. Dr. Bakri is a specialist in diseases and surgery of the retina and vitreous, in particular, age-related macular degeneration (AMD), diabetic retinopathy, and repair of complex retinal detachments. She undertakes both clinical and translational research in the pathogenesis and treatment of retinal diseases. She is active in teaching residents and fellows and has served as Director of the Medical and Surgical Retina Fellowships at Mayo Clinic.

Dr. Bakri completed a vitreoretinal fellowship at the Cleveland Clinic Foundation and her residency at Albany Medical College, NY. She graduated from the University of Nottingham Medical School, England. She has authored over 190 peer-reviewed papers and 17 book chapters on retinal diseases. She is a principal investigator on numerous multicenter clinical trials on novel drugs for retinal disease. She is the Editor-in-Chief of the book "Mayo Clinic on Vision and Eye Health," and is on the Editorial Boards of the American Journal of Ophthalmology, Retina, Seminars in Ophthalmology, and OSLI Retina. She is an active participant in several ophthalmic societies. She has served the Macula Society as Meeting Planning Chair and as an Executive Committee member, the American Society of Retinal Specialists as a

Board member and member of the Program Committee. She is a member of the Retina Society, serving on the Nominating Committee.

She has received numerous awards, including the Ophthalmologist Top 40 Under 40 award, a Senior Achievement Award from the American Academy of Ophthalmology, a Senior Honor Award from the American Society of Retina Specialists and was inducted into the Retina Hall of Fame. She recently received the Young Investigator Award from the American Society of Retina Specialists.

Andrew A. Moshfeghi, MD, MBA graduated from the University of Chicago in 1995 as a Small School Talent Search Scholar. He subsequently earned his medical degree from Tulane University School of Medicine. Following ophthalmology residency at North Shore University Hospital in New York, he received fellowship training in medical retina and vitreoretinal surgery at the University of Miami's Bascom Palmer Eye Institute. After joining the vitreoretinal service at Bascom Palmer, Dr. Moshfeghi received a full-tuition scholarship to attend the University of Miami Graduate School of Business Administration, where he received an MBA specializing in Health Sector Policy and Management. Dr. Moshfeghi is a board-certified ophthalmologist who is currently practicing vitreoretinal surgery at the University of Southern California's Roski Eye Institute in Los Angeles, where he serves as the director of the vitreoretinal surgery fellowship training program. In addition to his work with VBS, Dr. Moshfeghi is a member of the Retina Society, the Macula Society, and Club Vit. He also serves as the Co-Chair of the Fellowship Directors' Education & Training Committee for the American Society of Retina Specialists. Dr. Moshfeghi serves as an Editorial Board Member of OSLI Retina, Retinal Cases and Brief Reports, Retina Today, and Ocular Surgery News (Retina Section Editor). His research currently focuses on: 1) analysis of changing trends in retinal disease management and 2) evaluation of the structure-function relationship in patients with macular diseases, with a particular interest in metamorphopsia.



Philip J. Rosenfeld, MD, PhD is Professor of Ophthalmology at the Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. He is a vitreoretinal specialist with a primary clinical research interest in age-related macular degeneration (AMD). His major contributions include the clinical development of anti-VEGF therapies, the use of optical coherence tomography (OCT)–guided treatment regimens using anti-VEGF therapy, the clinical development of OCT instruments, and the development and use of novel OCT algorithms for the diagnosis and management of macular diseases. With a focus on age-related macular degeneration (AMD), Dr. Rosenfeld has been the principal investigator and study chairman for numerous AMD clinical trials. Of note, he was lead investigator in the Phase I/II/III ranibizumab (Genentech) trials and performed the 2-year PrONTO Study in which he pioneered the idea of OCT-guided, as-needed treatment as an alternative to monthly dosing with ranibizumab. He also pioneered the use of bevacizumab for exudative macular diseases, using both systemic and intravitreal drug delivery. In addition, Dr. Rosenfeld helped develop both spectral domain and swept source OCT platforms for commercial use in clinics, along with their imaging algorithms. He has been applying OCT angiography to study both non-exudative and exudative AMD with a particular interest in developing new OCT clinical trial anatomic endpoints for use in investigating novel therapies. Most recently, his research team has collaborated Dr. Ruikang Wang's research team and successfully used SS-OCT angiography to image non-exudative subclinical neovascularization, the choroid, and the choriocapillaris.

TOP 15 FINALISTS (in alphabetical order)

Finalist	Presentation Title
 **Ana Bastos de Carvalho, MD** Medical Retina Fellow Department of Ophthalmology & Visual Sciences University of Kentucky Lexington, KY	*Development and Optimization of a Telemedicine Network for Diabetic Retinopathy Screening in Primary Care Clinics*
 **Gena Damento, MD** Resident California Pacific Medical Center San Francisco, CA	*Incidence and Features of Uveal Melanoma in a Closed, Managed Care United States Population*
 **Michael P. Ellis, MD** Resident UC Davis Medical Center Sacramento, CA	*Cost Analysis of Tele-ophthalmology Screening for Diabetic Retinopathy Using Tele-health Billing Codes*
 **Brad Jacobsen, MD** Resident Moran Eye Center University of Utah Salt Lake City, UT	*Prevalence of Retinal Diseases and Associated Risk Factors in an African Population from Mwanza, Tanzania*
 **Rohan Jalalizadeh, MD** Resident Kellogg Eye Center University of Michigan Ann Arbor, MI	*Characteristics and Natural History of Lamellar Macular Holes: A Quantitative Analysis*
 **Jae Kim, MD, MS** Resident Kresge Eye Institute Wayne State University Detroit, MI	*Automated Program Design to Quantify Ellipsoid Zone Variation and Analyze its Relationship with the Visual Acuity of Patients with Diabetic Retinopathy*
 **Diana M. Laura, MD** Resident Bascom Palmer Eye Institute University of Miami Miller School of Medicine Miami, FL	*Genotypic and Phenotypic Antibiotic Resistance in Staphylococcus Epidermidis Endophthalmitis*
 **Anna G. Mackin, MD** Fellow University of Chicago Chicago, IL	*Adsorption of Complement Factor D by Polyacrylonitrile Microdialysis Membranes*

Finalist	Presentation Title
 **Fukutaro Mano, MD** Research Fellow Mayo Clinic Rochester, MN	*Evolution Towards a Reliable, Reproducible, and Safe Subretinal RPE Transplant Surgery*
 **Neesurg Mehta, MD** Resident New York Eye and Ear Infirmary of Mount Sinai New York, NY	*Correlation of OCT-Angiography Vessel Densities and the Early Treatment Diabetic Retinopathy Study Grading Scale*
 **Shravani Mikkilineni, MD, MBA** Resident Henry Ford Hospital Detroit, MI	*T2 Magnetic Resonance Assay for Detection of Ocular Candidiasis*
 **Chirag M. Shah, MD, MPH** Resident University of California Irvine Irvine, CA	*Retinal Morphology and Its Influence on Operative Outcomes in Refractive Lens Exchange Patients (Cataract, Lens, and Refractive Optical Coherence Tomography (CLARO) Study)*
 **Joseph Simonett, MD** Resident Casey Eye Institute Oregon Health & Science University Portland, OR	*Blood Brain Barrier Disruption Maculopathy: A Common, Visually Significant Side-effect in a Growing Population*
 **Guneet Singh Sodhi, MD** Resident Eastern Virginia Medical School Norfolk, VA	*The T.A.M.E. cCSC (Treat and Maintain Eplerenone for Chronic Central Serous Chorioretinopathy) Study Using Predictive Biomarkers*
 **Matthew Starr, MD** Residency Graduate Mayo Clinic Rochester, MN First Year Vitreoretinal Fellow Mid Atlantic Retina, Wills Eye Hospital Philadelphia, PA	*20 Year Incidence of Macular Telangiectasia Type 2 and Associated Systemic Comorbidities*

AGENDA

Time	Detail	Presenter(s)
4:00pm	Welcome & Introductions	Sheryl Stevenson, *Ophthalmology Times* Group Editorial Director
4:05pm	Program Overview & Introduction of Judges	Rishi P. Singh, MD—Program Chair Thomas A. Albini, MD—Judge Sophie J. Bakri, MD—Judge Andrew A. Moshfeghi, MD—Judge Philip J. Rosenfeld, MD, PhD—Judge and Keynote speaker
4:10pm	Presentations begin **Each Fellow/Resident presenter will have 7 minutes to present followed by 3 minutes of feedback from the judges*	Presentation Order: Assigned onsite upon check-in
5:00pm	15 Minute Break	
6:05pm	10 Minute Break	
7:05pm	Awards Reception	
7:20pm	Keynote Speaker	Philip J. Rosenfeld, MD, PhD
	Awards Presentation: Top 5 (which will be published in *OSLI Retina* in 2020) » 5th Place Finalist » 4th Place Finalist » 3rd Place Finalist » 2nd Place Finalist » 1st Place Winner	Rishi P. Singh, MD—Program Chair
8:30pm	Program Concludes	

Ophthalmology Times

AN MH life sciences BRAND

Ophthalmology Times wishes to thank the sponsor of this program, our expert panel of judges, and the participants of the 2019 *Ophthalmology Times* Research Scholar Honoree program.

REGENERON